ProShares Joins Pershing’s FundVest® ETF No-Transaction-Fee Platform with Seven Funds
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Business Wire
BETHESDA, Md.--(BUSINESS WIRE)-- ProShares, a premier provider of ETFs, announced that it has joined FundVest® ETF, the no-transaction-fee exchange traded fund platform by BNY Mellon’s Pershing (“Pershing”). The seven ETFs include ProShares’ popular Dividend Aristocrats®, Large Cap Core Plus and Global Infrastructure funds. "No-transaction-fee platforms are gaining popularity, as investors look to reduce costs within their investment portfolios," said Steve Cohen, managing director at ProShares. “Our inclusion in the Pershing no-transaction-fee platform will allow financial professionals and their clients to further leverage the ProShares ETF lineup in a cost-effective manner." The seven ProShares funds that became available on Pershing's FundVest® ETF platform as of June 13, 2019 are: Fund Name
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
- Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)GlobeNewswire
- Zenas BioPharma to Participate in Upcoming Healthcare Investor ConferencesGlobeNewswire
- Zenas Bio: Recent IPO With Late-Stage Candidate [Seeking Alpha]Seeking Alpha
ZBIO
Sec Filings
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- 12/4/24 - Form 4
- ZBIO's page on the SEC website